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ABSTRACT
Objectives To characterise peripheral musculoskeletal 
involvement in patients with spondyloarthritis (SpA) 
including psoriatic arthritis (PsA), across the world.
Methods Cross- sectional study with 24 participating 
countries. Patients with a diagnosis of axial SpA 
(axSpA), peripheral SpA (pSpA) or PsA according to their 
rheumatologist were included. The investigators were 
asked which diagnosis out of a list of six (axSpA, PsA, 
pSpA, inflammatory bowel disease- associated SpA, 
reactive arthritis or juvenile SpA (Juv- SpA)) fitted the 
patient best. Peripheral manifestations (ie, peripheral joint 
disease, enthesitis, dactylitis and root joint disease), their 
localisation and treatments were evaluated.
Results A total of 4465 patients were included (61% men, 
mean age 44.5 years) from four geographic areas: Latin 
America (n=538), Europe plus North America (n=1677), 
Asia (n=975) and the Middle East plus North Africa 
(n=1275). Of those, 78% had ever suffered from at least 
one peripheral musculoskeletal manifestation; 57% had 
peripheral joint disease, 44% had enthesitis and 15% had 
dactylitis. Latin American had far more often peripheral 
joint disease (80%) than patients from other areas. 
Patients with PsA had predominantly upper limb and small 
joint involvement (52%).
Hip and shoulder involvement was found in 34% of 
patients. The prevalence of enthesitis ranged between 
41% in patients with axSpA and 65% in patients with Juv- 
SpA. Dactylitis was most frequent among patients with PsA 
(37%).
Conclusion These results suggest that all peripheral 
features can be found in all subtypes of SpA, and that 
Key messages
What is already known about this subject?
 ► Peripheral musculoskeletal manifestations are a 
hallmark of psoriatic arthritis (PsA) and occur also 
in spondyloarthritis (SpA), but their distribution and 
worldwide prevalence have sparsely been studied in 
SpA and specifically in axial SpA (axSpA).
What does this study add?
 ► This study demonstrates that all types of peripheral 
musculoskeletal manifestations can be found in all 
subtypes of SpA.
 ► This study allowed to directly compare the world-
wide SpA (including PsA) population across the dif-
ferent geographic areas, and demonstrated a high 
inter- region variability in the prevalence of these 
manifestations.
 ► There is a large overlap of peripheral manifestations 
across the different SpA subtypes, suggesting a high 
prevalence of peripheral features in axSpA and quite 
similar prevalences in peripheral SpA and PsA.
How might this impact on clinical practice or 
future developments?
 ► This study suggests that SpA constitutes one entity 
with different phenotypic presentations (including 
PsA).
 ► This study confirms that peripheral musculoskeletal 
manifestations should be studied in the entire group 
of SpA rather than in its subgroups alone.
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differences are quantitative rather than qualitative. In a high proportion 
of patients, axial and peripheral manifestations coincided. These findings 
reconfirm SpA clinical subtypes are descendants of the same underlying 
disease, called SpA.
INTRODUCTION
Spondyloarthritis (SpA) mainly affects the axial skeleton 
and sacroiliac joints but may affect peripheral structures 
too.1 Peripheral involvement has always been impor-
tant in the nomenclature of the diverse forms of SpA. 
The traditional classification includes several subtypes, 
such as ankylosing spondylitis (AS), psoriatic arthritis 
(PsA), inflammatory bowel disease (IBD)- associated 
SpA, reactive arthritis (ReA) and juvenile SpA (Juv- SpA), 
depending on the presence of peripheral and/or extra-
musculoskeletal manifestations.1 In 2009, the Assessment 
of Spondyloarthritis international Society (ASAS) has 
introduced the concept of axial (axSpA) and peripheral 
SpA (pSpA) and developed new classification- criteria 
making this distinction.2 In parallel, and independently, 
the Group for Research and Assessment of Psoriasis 
and Psoriatic Arthritis (GRAPPA) has proposed specific 
criteria for the classification of PsA.3 Guided by the reality 
of drug development in the field, the US Food and Drug 
Administration and the European Medicine Agency have 
proposed specific guidance for drug development limited 
to three (four) diseases (axSpA (radiographic and non- 
radiographic (AS)), pSpA and PsA), which to some extent 
ignores the reality of SpA as an umbrella entity. This plei-
otropy has created dilemmas in the field, since patients 
with peripheral manifestations, that can occur across the 
entire spectrum of patients with SpA, may easily meet the 
criteria for more than one disease at the same time, or 
alternatively may fit distinct criteria over time. Similarly, 
patients with a SpA- associated diagnosis characterised by 
peripheral involvement may also present with axial symp-
toms. Finally, it is suggested that distributions of periph-
eral manifestations of SpA may differ across geograph-
ical areas. It is well known, for example, that the preva-
lence of peripheral arthritis in Latin American patients 
with SpA is higher than in Europe4 5 and that peripheral 
involvement of SpA in Asia is rather low.6
The study of phenotypical distributions has classically 
evolved along the axes of scientific and professional 
organisations (eg, GRAPPA vs ASAS), which focused on 
either peripheral or axial involvement. In addition, ASAS 
classically had a European dominance, while GRAPPA 
had a solid North American basis. Moreover, in the 
majority of previous SpA cohorts, these manifestations 
(either axial or peripheral) were used as entry criterion, 
limiting the evaluation of the whole SpA spectrum. These 
distinctions imply and explain why a thorough compar-
ison of peripheral manifestations in the SpA spectrum, 
with involvement of countries around the world, has 
never been conducted so far. This has prompted us to 
design the ASAS- PerSpA study, which aimed at comparing 
the prevalence, characteristics and treatments of periph-
eral musculoskeletal manifestations in patients with all 
possible subtypes of SpA across all regions of the world. 
The investigators were also interested to see how often 
peripheral and axial manifestations in patients with a SpA 
diagnosis coincide, and if there are global differences.
METHODS
Study design
PerSpA was a multinational observational, cross- sectional 
study with 24 participating countries worldwide.
Patient recruitment
For this study, the scientific committee appointed one 
national principal investigator (an ASAS member) for 
each participating country. Several countries per conti-
nent were selected and the national principal investi-
gators invited rheumatologists from their countries to 
participate. Consecutive adult patients (ie, at least 18 
years old) with a diagnosis of axSpA, pSpA or PsA, who 
were able to understand and complete questionnaires, 
were included from July 2018 to February 2020.
Data collection
A specific case report form was used to collect four 
different categories of data:
1. Demographics: country, age, sex, body mass index, smok-
ing, alcohol intake and the highest level of education 
completed.
2. Disease characteristics: the investigators were asked to 
name the diagnosis that in their opinion best described 
the disease of the patient irrespective of the fulfilment 
of any classification criteria. They could choose from 
the following list: axSpA, PsA, pSpA, IBD- related SpA, 
ReA, Juv- SpA or they could name another disease.
In addition, information about HLA- B27 status, first- 
degree or second- degree relatives (with AS, psoriasis, 
uveitis, ReA or IBD), axial involvement (defined with 
the question “Do you consider that this patient has 
ever suffered from axial involvement of SpA?”), in-
formation concerning the presence of sacroiliitis on 
radiographs, uveitis, psoriasis confirmed by a derma-
tologist, IBD confirmed by endoscopy and treatment 
(non- steroidal anti- inflammatory drugs (NSAIDs), 
glucocorticoids, conventional synthetic (cs) and bi-
ological (b) disease- modifying antirheumatic drugs 
(DMARDs)) were collected.
3. Peripheral musculoskeletal manifestations: included (a) 
peripheral joint disease (excluding root joints) in 
the past, the presence of objective signs of synovi-
tis (ie, physical examination by a rheumatologist or 
confirmed by ultrasonography), a monoarticular, 
oligoarticular or polyarticular pattern, localisation 
(predominantly in the lower limbs/large joints) and 
natural history (transient, continuous, intermittent or 
progressive); (b) ‘root- joint’ (ie, hip and shoulder) 
involvement in the past according to the rheumatol-
ogist, (c) midfoot arthritis (tarsitis) in the past as well 
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as confirmed by specific investigations; (d) enthesitis 
in the past confirmed and non- confirmed by specific 
tests (ie, sonography, radiographs, MRI or bone scin-
tigraphy), localisation and natural history (single epi-
sode, intermittent, continuous or progressive) and (e) 
the occurrence of dactylitis in the past and localisation 
(fingers or toes) were collected. Moreover, the pres-
ence of current peripheral musculoskeletal manifes-
tations at the moment of the study visit was evaluated 
based on physical examination. Investigators were also 
asked about specific treatments (NSAIDs, oral and 
intra- articular glucocorticoids, csDMARDs and bD-
MARDs) prescribed for each of these peripheral mus-
culoskeletal manifestations using the questions ‘Did 
this manifestation require a specific treatment?’ and 
‘if yes, which one?’
4. Clinimetric information: current disease activity at the 
moment of the study visit was measured by the Bath 
Ankylosing Spondylitis Disease Activity Index7 and 
the Ankylosing Spondylitis Disease Activity Score- C re-
active protein (ASDAS- CRP).8 Moreover, the Ritchie 
Articular Index,9 66 Swollen Joints Index,10 Mander 
enthesitis index (MEI),11 Leeds Enthesitis Index12 
and the Spondyloarthritis Research Consortium of 
Canada enthesitis score13 were assessed. The Bath 
Ankylosing Spondylitis Functional Index and the 
ASAS Health Index were used to evaluate function 
and health, respectively.14 15 Finally, the presence of 
secondary fibromyalgia according to the rheumatol-
ogist’s opinion was collected and the self- reported 
Fibromyalgia Rapid Screening Tool (FiRST) was 
completed.16
All information was obtained by a study investigator 
or research nurse during a face- to- face interview at one 
single study visit, which included a review of the medical 
record. A centralised electronic case report form was 
used to enter the data.
Statistical analysis
Patients were stratified in four geographic areas: Latin 
America (Argentina, Chile, Colombia and Mexico), 
Europe and North America (Canada, France, Germany, 
Hungary, Italy, Portugal, Romania, Spain, the Nether-
lands, the UK and the USA), Asia (China, India, Japan, 
South Korea and Taiwan) and the Middle East and 
North Africa (Egypt, Lebanon, Morocco and Turkey). 
North America and Europe were grouped together 
because the numbers of patients from the USA and 
Canada were low.
Patients were also grouped according to the best- fit 
diagnosis (axSpA, PsA, pSpA, IBD- SpA, ReA, Juv- SpA or 
alternatives). The analysis was purely descriptive. The 
prevalence of each peripheral musculoskeletal mani-
festation was estimated and information about such 
manifestations (locations, natural history and specific 
treatments) was examined with regard to the geographic 
area and to the diagnosis.
RESULTS
Demographics and disease characteristics
Investigators from 24 countries recruited a total of 4538 
consecutive patients fulfilling the inclusion criteria. 
Seventy- three patients were excluded because of missing 
data, and 4465 patients were included in the analysis. The 
number of patients included per country is summarised 
in online supplemental table S1. Latin America (12%), 
Europe and North America (38%), Asia (22%) and 
the Middle East plus North Africa (29%) were properly 
represented. North America and Europe were grouped 
together because the enrolled patients in the USA and 
Canada were low (only 110 patients). The best- fit diag-
noses (in decreasing order) was axSpA (61%), followed 
by PsA (23%), pSpA (9.7%), SpA- IBD (2.5%), ReA 
(1.3%), other SpA (1.3%) and Juv- SpA (1.2%). Demo-
graphics, clinical characteristics, disease activity and 
disease burden with regard to the diagnosis are shown in 
table 1. The prevalence of the HLA- B27 antigen ranged 
between 18.2% in patients with PsA and 79% in patients 
with axSpA. Uveitis was found less frequently in patients 
with PsA (2.6%) and more frequently in patients with 
axSpA (22%). Patients with PsA had the highest preva-
lence of psoriasis confirmed by a dermatologist (87%) 
while patients with ReA and IBD- SpA had the lowest 
prevalence (3%). Remarkably, 55% of patients with pSpA 
and 36% of patients with PsA had axial involvement 
according to the rheumatologist, and 52% of patients 
with axSpA had ever used csDMARDs. At the moment of 
the study visit, the prevalence of patients with low disease 
activity (ASDAS- CRP <2.1) ranged between 36% in pSpA 
and 41% in axSpA. Online supplemental table S2 shows 
the same information with regard to the geographic area. 
HLA- B27 was more frequent among Asian patients (80%) 
and less frequent among patients from Middle East and 
North Africa (54%). Asian patients also had the highest 
prevalence of axial involvement according to the rheu-
matologist (82%), while only 66% of Latin American 
patients had axial involvement. Finally, IBD was more 
prevalent among Middle East and North African patients 
(8%) and less prevalent among Asian patients (3%).
Peripheral musculoskeletal manifestations
Of all patients, 78% had suffered at least once from 
a peripheral musculoskeletal manifestation (either 
peripheral joint disease, root joint involvement, tarsitis, 
enthesitis or dactylitis). The lowest prevalence was found 
in axSpA (66%), the highest expectedly in pSpA (99%). 
The prevalence of musculoskeletal manifestations was 
plotted against geographic area and diagnosis in figures 1 
and 2, respectively. At the moment of the study visit, 32% 
of patients had at least one current peripheral musculo-
skeletal manifestation on physical examination (23% of 
patients with axSpA and 49% of patients with pSpA).
Peripheral joint disease (excluding root joints)
Peripheral joint disease (excluding root joints) was the 
most frequent peripheral musculoskeletal manifestation 
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Age, mean (SD) 42.0 (13.0) 44.2 (14.4) 51.8 (13.0) 44.8 (14.5) 37.5 (16.6)
Gender (men) 68.3% 46.9% 48.5% 55.4% 61.6%
Region
Latin America 10.2% 8.1% 17.0% 14.9% 23.2%
Europe and North America 37.2% 23.5% 47.3% 23.8% 30.4%
Asia 22.4% 31.9% 16.0% 20.2% 25.0%
Middle East and North 
Africa
30.2% 36.5% 19.7% 41.1% 21.4%
BMI (kg/m2), mean (SD) 25.9 (5.1) 26.3 (5.4) 28.0 (5.9) 25.2 (4.9) 24.1 (4.8)
Ever smoker 1185/2717 (43.6%) 128/432 (29.6%) 494/1032 (47.9%) 36.9% 27.7%
Ever alcohol 1089/2718 (40.1%) 179/432 (41.4%) 451/1032 (43.7%) 36.3% 28.6%
University education 1178/2717 (43.4%) 45.5% 320/1032 (31.0%) 44.0% 41.1%
Fibromyalgia 
(rheumatologist’s opinion)
212/2717 (7.8%) 11.1% 11.6% 9.5% 3.6%
Fibromyalgia (FiRST) 427/2482 (17.2%) 69/391 (17.6%) 245/982 (24.9%) 25/165 (15.2%) 9/107 (8.4%)
Symptom duration (years), 
mean (SD)
14.4 (11.1) 10.1 (9.5) 16.8 (12.3) 12.7 (10.7) 10.7 (8.8)
Diagnosis delay (years), 
mean (SD)
5.8 (7.7) 4.3 (6.6) 9.1 (11.1) 6.9 (8.5) 4.0 (6.6)
HLA- B27 positive 1709/2168 (78.8%) 197/316 (62.3%) 86/474 (18.2%) 27/85 (31.8%) 47/77 (61.0%)
First- degree or second- 
degree relatives of SpA*
35.5% 28.9% 36.3% 22.0% 27.7%
Axial involvement 
(according to the 
rheumatologist)
97.5% 55.0% 35.5% 58.3% 66.1%
Sacroiliitis on X- ray 75.1% 33.7% 20.5% 37.5% 48.2%
Uveitis ever 21.6% 17.3% 2.6% 16.1% 18.8%
IBD ever (confirmed by 
endoscopy)
4.7% 4.4% 0.5% 64.3% 1.8%
Psoriasis ever (confirmed 
by a dermatologist)
154/2718 (5.7%) 12.2% 86.5% 3.0% 8.9%
csDMARDs ever 51.6% 88.7% 92.8% 92.9% 76.8%
bDMARDs ever 59.3% 51.5% 64.7% 53.0% 48.2%
Current csDMARDs 23.1% 53.1% 59.6% 52.4% 49.1%
Current bDMARDs 47.5% 37.0% 51.6% 38.1% 33.9%
NSAIDs alone 30.5% 15.0% 10.8% 12.5% 23.2%
CRP mg/L, mean (SD) 11.7 (26.6) 13.9 (25.4) 11.4 (28.6) 13.1 (22.5) 12.8 (20.3)
CRP ≥6 mg/L 1142/2295 (49.8%) 48.0% 412/1028 (40.1%) 42.9% 46.4%
ASDAS- CRP, mean (SD) 2.5 (1.1) 2.6 (1.2) 2.6 (1.1) 2.5 (1.1) 2.5 (1.1)
ASDAS- CRP <1.3 457/2682 (17.0%) 67/428 (15.7%) 147/1015 (14.5%) 30/167 (18.0%) 20/110 (18.2%)
ASDAS- CRP <2.1 1088/2682 (40.6%) 153/428 (35.7%) 379/1015 (37.3%) 64/167 (38.3%) 41/110 (37.3%)
PGA, mean (SD) 4.3 (2.7) 4.5 (2.7) 4.6 (2.7) 4.3 (2.7) 4.4 (2.8)
BASDAI, mean (SD) 3.7 (2.4) 4.0 (2.4) 4.3 (2.5) 3.8 (2.4) 3.7 (2.5)
BASFI, mean (SD) 3.0 (2.6) 2.8 (2.6) 3.1 (2.8) 2.8 (2.6) 3.0 (2.7)
ASAS- HI, mean (SD) 6.3 (4.5) 6.6 (4.4) 7.2 (4.7) 6.2 (4.2) 7.4 (4.7)
Peripheral manifestations
Peripheral joint disease in 
the past
36.0% 94.7% 90.8% 77.4% 75.9%
Continued
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in the whole population with a prevalence of 57% (51% 
had objective signs of synovitis). The geographical distri-
bution of peripheral joint disease differed importantly: 
patients from Latin American countries showed the 
highest prevalence (80%). According to the diagnosis, 
the lowest prevalence of peripheral joint disease was 
found in patients with axSpA (36%), while the highest 
frequency was found in patients with pSpA and PsA (95% 
and 91%, respectively).
The number of affected joints with regard to diagnosis 
is illustrated in figure 3. Among the whole population with 
peripheral joint disease, 12%, 44% and 44% of patients 
showed monoarticular, oligoarticular and polyarticular 
involvement, respectively. But patients with a diagnosis of 
PsA had predominantly polyarticular involvement (60%), 
while patients with a diagnosis of ReA or IBD- SpA had 
predominantly oligoarticular disease (68%). Monoartic-
ular involvement was rare in all groups.
Of all patients with peripheral joint disease, 39% had 
predominantly lower limb and large joint involvement 
(figure 4); 31% had only peripheral joint disease of small 












Peripheral joint disease 
in the past confirmed by 
specific investigations
30.2% 88.9% 85.7% 72.6% 72.3%
Root joints involvement in 
the past
33.9% 44.3% 26.7% 32.7% 52.7%
Midfoot arthritis (tarsitis) in 
the past
5.2% 13.6% 10.3% 9.5% 18.8%
Midfoot arthritis (tarsitis) 
in the past confirmed by 
specific investigations
1.5% 3.7% 3.1% 3.0% 4.5%
Any enthesitis in the past 40.9% 57.3% 45.8% 45.8% 65.2%
Any enthesitis in the past 
confirmed by specific 
investigations
12.9% 25.9% 23.3% 18.5% 27.7%
Dactylitis in the past 6.0% 23.1% 37.0% 12.5% 16.1%
Number of current swollen 
joints, mean (SD)
0.3 (2.0) 1.2 (2.9) 1.9 (4.8) 0.7 (1.7) 1.1 (6.3)
Any current swollen joint 281/2716 (10.3%) 41.6% 410/1032 (39.7%) 23.8% 24.1%
Number of current tender 
joints, mean (SD)
1.5 (4.4) 3.3 (6.2) 4.8 (8.7) 2.7 (5.5) 2.1 (5.2)
Any current tender joint 928/2716 (34.2%) 271/433 (62.6%) 651/1032 (63.1%) 53.0% 50.9%
Current MEI score, mean 
(SD)
2.2 (5.5.) 2.4 (5.7) 2.9 (7.6) 3.0 (6.3) 2.1 (4.4)
Number of current 
enthesitis according to the 
MEI†, mean (SD)
0.6 (1.8) 0.6 (2.1) 0.8 (2.7) 0.8 (1.9) 0.7 (1.7)
Any current enthesitis 
according to the MEI†
455/2716 (16.8%) 18.2% 191/1032 (18.5%) 25.6% 20.5%
Any current enthesitis 
according to the SPARCC 
Enthesitis Index
221/2716 (8.1%) 15.2% 143/1032 (13.9%) 16.1% 10.7%
Any current enthesitis 
according to the LEI
174/2716 (6.4%) 12.2% 106/1032 (10.3%) 10.1% 9.8%
All results are presented as mean and SD and percentages for continuous and categorical variables, respectively.
*First- degree or second- degree relatives with ankylosing spondylitis, psoriasis, uveitis, reactive arthritis or IBD.
†Enthesis with a score >1 according to the MEI.
ASAS- HI, ASAS Health Index; ASDAS- CRP, Ankylosing Spondylitis Disease Activity Score; AxSpA, axial spondyloarthritis; BASDAI, 
Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARDs, biological disease- 
modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; csDMARDs, conventional synthetic disease- modifying 
antirheumatic drugs; FiRST, Fibromyalgia Rapid Screening Tool; IBD, inflammatory bowel disease; IBD- SpA, inflammatory bowel 
disease- associated spondyloarthritis; SPARCC Enthesitis Index, Spondyloarthritis Research Consortium of Canada Enthesitis Index; 
Juv- SpA, juvenile spondyloarthritis; LEI, Leeds Enthesitis Index; MEI, Mander Enthesitis Index; PGA, Patient’s Global Assessment; PsA, 
psoriatic arthritis; pSpA, peripheral spondyloarthritis; ReA, reactive arthritis.;
Table 1 Continued
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of patients with predominantly lower limb and large joint 
involvement was similar in patients with pSpA (51%) and 
axSpA (49%). Of the patients with a diagnosis of PsA, 52% 
had predominantly upper limb and small joint involvement.
Despite the use of bDMARDs at the moment of the 
study visit was more frequent among patients with axSpA 
than in pSpA (51.6% vs 47.5%, respectively), patients 
with pSpA showed the highest prevalence of at least 
one swollen joint on physical examination (42%) and 
patients with axSpA showed the lowest prevalence (10%) 
(table 1).
csDMARDs and bDMARDs specifically for peripheral 
joint disease were used in 77% and 42% of patients, 
respectively, while systemic glucocorticoids and local 
injections were used in 43% and 31%, respectively 
(table 2).
Root joint involvement
Root joint involvement (ie, hip or shoulder) occurred 
among all subtypes but ranged between 27% in patients 
with PsA and 53% in patients with Juv- SpA. Asian patients 
had most root joint involvement (55%) in comparison 
with the other regions. Among patients with root joint 
involvement and available data concerning the location 
(figure 5), hip involvement alone was found in 57%, 
being most frequent in axSpA (65%), whereas shoulder 
involvement alone was found in 21%, being more prev-
alent in patients with PsA (43%). The highest preva-
lence of hip and shoulder involvement occurring in the 
same individual was found in patients with pSpA (32%). 
Among patients with root joint involvement, 30% initi-
ated bDMARDs specifically for this symptom, while 9% 
required total articular replacement (table 2).
Figure 1 Prevalence of peripheral musculoskeletal manifestations in the past with regard to the geographic area.
Figure 2 Prevalence of peripheral musculoskeletal manifestations in the past with regard to the diagnosis. axSpA, axial 
spondyloarthritis; IBD- SpA, inflammatory bowel disease- associated spondyloarthritis; Juv- SpA, juvenile spondyloarthritis; PsA, 
psoriatic arthritis; pSpA, peripheral spondyloarthritis; ReA, reactive arthritis.
 on F










pen: first published as 10.1136/rm




7López- Medina C, et al. RMD Open 2021;7:e001450. doi:10.1136/rmdopen-2020-001450
Spondyloarthritis
Midfoot arthritis (tarsitis)
A total of 344 patients in the overall population had ever 
suffered from midfoot arthritis (tarsitis), representing 
7.7% (2.2% confirmed by specific investigations). The 
prevalence of tarsitis ranged between 5.2% in patients 
with axSpA and 19% in patients with Juv- SpA. With 
regard to the region, this frequency ranged between 
3.5% in Middle East and North African patients and 24% 
in Latin American patients.
Enthesitis
Of all patients, 44% had ever suffered from any enthesitis 
(17% had imaging- confirmed enthesitis). Enthesitis was 
more prevalent in Latin America (61%) than in other 
countries (approximately 40%). Enthesitis was more 
prevalent in patients with Juv- SpA (65%) than in other 
patients (approximately 45%).
The heel (either the insertion of the Achilles tendon 
or the plantar fascia) was by far the most frequent first 
Figure 3 Number of affected joints in the past (excluding root joints) with regard to the diagnosis*. *Among patients with 
peripheral joint disease (excluding root joints) and available data concerning the number of affected joints (n=2538). axSpA, 
axial spondyloarthritis; IBD- SpA, inflammatory bowel disease- associated spondyloarthritis; Juv- SpA, juvenile spondyloarthritis; 
PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; ReA, reactive arthritis.
Figure 4 Location of peripheral articular involvement in the past (excluding root joints) with regard to the diagnosis*. *Among 
patients with peripheral joint disease (excluding root joints) and available data concerning the location of affected joints 
(n=2501). axSpA, axial spondyloarthritis; IBD- SpA, inflammatory bowel disease- associated spondyloarthritis; Juv- SpA, juvenile 
spondyloarthritis; PsA, psoriatic arthritis; pSpA, peripheral spondyloarthritis; ReA, reactive arthritis.
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location for enthesitis (69%). The course of enthesitis 
(online supplemental figure S1) was intermittent (55%), 
continuous (21%), monophasic (19%) or progressive 
(12%). The mean number of locations was 4.3 (4.6), and 
slightly higher in patients with a diagnosis of PsA (4.8 
(5.3)) (online supplemental figures S2 and S3).
At the moment of the study visit, 18% of patients had 
enthesitis according to the MEI on physical examination 












NSAIDs 1191 (79.2%) 2317 (91.2%) 1318 (66.4%) 489 (71.4%)
  Prescribed for >1 peripheral 
manifestation
925/1191 (77.7%) 1449/2317 (62.5%) 1052/1318 (79.8%) 467/489 (95.5%)
Systemic glucocorticoids NC 1100 (43.3%) 289 (14.6%) NC
  Prescribed for >1 peripheral 
manifestation
235/1100 (21.4%) 235/1984 (11.8%)
csDMARDs 686 (45.6%) 1962 (77.2%) 665 (33.5%) 377 (55.0%)
  Prescribed for >1 peripheral 
manifestation
561/686 (81.8%) 976/1962 (49.7%) 561/665 (84.4%) 354/377 (93.9%)
bDMARDs 455 (30.3%) 1066 (42.0%) 443 (22.3%) 177 (25.8%)
  Prescribed for >1 peripheral 
manifestation
302/455 (66.4%) 521/1066 (48.9%) 344/443 (77.7%) 164/177 (92.7%)
Local injections glucocorticoids 215 (14.3%) 778 (30.6%) 161 (8.1%) 89 (13.0%)
  Prescribed for >1 peripheral 
manifestation
101/215 (47.0%) 207/778 (26.6%) 83/161 (51.6%) 61/89 (68.5%)
Total articular replacement 136 (9.0%) 20 (0.8%) NC NC
  Prescribed for >1 peripheral 
manifestation
4/136 (2.9%) 4/20 (20.0%)
Any treatment 1251 (83.2%) 2457 (96.7%) 1364 (68.8%) 536 (78.2%)
*Data concerning treatment for midfoot arthritis were not collected.
bDMARDs, biological disease- modifying antirheumatic drugs; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; 
NC, not collected; NSAIDs, non- steroidal anti- inflammatory drugs.
Figure 5 Location of root joint involvement in the past with regard to the diagnosis*. *Among patients with root joint 
involvement and available data concerning the location (n=1372). axSpA, axial spondyloarthritis; IBD- SpA, inflammatory 
bowel disease- associated spondyloarthritis; Juv- SpA, juvenile spondyloarthritis; PsA, psoriatic arthritis; pSpA, peripheral 
spondyloarthritis; ReA, reactive arthritis.
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(ie, at least one enthesis with a score >1), less often in 
patients with axSpA (17%) and more often in patients 
with ReA and IBD- SpA (26%) (table 1).
The specific treatment used for enthesitis is described 
in table 2. Remarkably, only 8.1% of patients received 
local injections with glucocorticoids, and 34% received 
csDMARDs specifically for this symptom.
Dactylitis
Of all patients, 15% had ever dactylitis. Expectedly, the 
prevalence was highest in the patients with a diagnosis 
of PsA (37%) and lowest in patients with axSpA (6%) 
(figure 1). Dactylitis was slightly more frequent in fingers 
(62%) than in toes (59%) and occurred in both in 
21%. Finger involvement was slightly more prevalent in 
patients with ReA and IBD- SpA but patients with Juv- SpA 
had more toe involvement than others(online supple-
mental figure S4).
Dactylitis was more prevalent in the Latin American 
countries (26%) than in other regions of the world 
(approximately 15%).
Concerning treatment, 55% of patients received 
csDMARDs specifically for dactylitis, 26% bDMARDs 
and 13% had received local injections of glucocorticoids 
(table 2).
DISCUSSION
This large multinational study has addressed periph-
eral musculoskeletal manifestations in patients with 
diagnoses of the broader spectrum of SpA. Contrary 
to previous studies that have shown the prevalence of 
peripheral manifestations about 30%–40% in patients 
with axSpA, the current study revealed a high prevalence 
of peripheral manifestations (66%) in these patients. 
This shows that in spite of the term ‘spondyloarthritis’, 
which suggests the spine is the dominant locus of inflam-
mation, peripheral signs and symptoms form an integral 
part of the phenotype. Another remarkable observation 
was the high prevalence of axial symptoms found in a 
study focusing on peripheral manifestations occurring in 
the broader SpA- spectrum. It is unlikely that this obser-
vation reflects selection bias invoked by axSpA experts, 
since only half of the investigators were ASAS members. It 
reinforces the suggestion that peripheral and axial mani-
festations are ‘two lots of the same tribe’ (the tribe of 
SpA) and that differences in frequency and distribution 
determine the clinical diagnosis by the rheumatologist.
The most frequently reported peripheral manifestation 
was peripheral joint disease (57% of all patients) and the 
prevalence was roughly similar in both PsA and pSpA (91% 
and 95%, respectively). This prevalence is similar to that 
reported in studies focusing on pSpA, in which peripheral 
arthritis was found in approximately 94% patients.17 18 Our 
results confirm previous studies reporting a greater prev-
alence of peripheral arthritis and enthesitis in patients in 
Latin America compared with those in European and the 
Middle East.5 19 One plausible explanation for this finding 
could be, on one hand, the lower prevalence of the HLA- B27 
antigen in Latin American populations (60% in Latin Amer-
icans vs 80% in Asian patients in our study), which has been 
classically associated with axial involvement, as well as by the 
higher prevalence of psoriasis in this geographic area.20 On 
the other hand, lifestyle and other factors such as micro-
biome may play a role in the higher prevalence of periph-
eral manifestations.21 HLA- B27 has a low prevalence in both 
Middle East and North Africa as well as in some Asian coun-
tries such as Japan. So, the lower prevalence of HLA- B27 in 
the Middle East and North Africa was expected. The higher 
prevalence in Asian countries was likely due to a selection 
of patients positive for HLA- B27 among the patients seen 
in clinics. IBD (which is not clearly linked to HLA- B27) was 
nevertheless higher among patients in the Middle East and 
North Africa and lower in Asia. This is most likely a finding 
independent of the prevalence of HLA- B27. Together, these 
data point to differences between regions in the interpreta-
tion of certain SpA features with regard to making a clinical 
diagnosis.
Peripheral joint disease was mainly oligoarticular and poly-
articular involvement and rarely monoarticular. As expected, 
this distribution differed across diagnoses: polyarticular 
involvement was more often found in patients with PsA, 
whereas oligoarticular and monoarticular involvement was 
most often found in patients with axSpA. In terms of local-
isation, peripheral joint disease in SpA has classically been 
considered to occur predominantly in lower limbs and large 
joints.22 Unlike previous cohorts, this study had only 39% 
of patients with peripheral involvement of large joints of 
lower extremity, which was mainly reported in patients with 
pSpA, ReA and IBD- SpA. However, patients with PsA had 
predominantly upper limb and small joints involvement. 
This means, a predilection of joint involvement is among 
the most important phenotypical differences between PsA 
and peripheral SpA, two entities that otherwise seem to be 
remarkably identical.
Hip involvement is a classical feature in patients with 
more severe axial disease, which led Amor et al23 to 
consider hip involvement as a severity criterion of SpA. 
These findings gave rise to the hypothesis that hips, 
together with the shoulders, should be considered ‘root 
joints’, behaving more similarly to the spine than to other 
peripheral joints.24 25 The majority of studies evaluating 
hip involvement focused on axSpA, and data for shoulder 
involvement are scarce. The PerSpA study explored 
root joint involvement in the whole population of SpA. 
Overall, not less than 34% reported root joint involve-
ment in the past, especially in Asian participants. Inter-
estingly, the highest prevalence was found in patients 
with Juv- SpA. Previous studies have also demonstrated 
that patients with a juvenile onset of SpA (ie, <16 years) 
are at highest risk of developing hip disease followed by 
hip replacement.26 In terms of location, hip involvement 
alone was found in 57% of those with root joints involved, 
but hip and shoulder involvement in combination was 
found in not less than 22% of patients. Expectedly, hip 
involvement (with or without shoulder involvement) was 
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highest in patients with axSpA, confirming the known 
association. But still, half of patients with PsA reported 
root joint involvement especially shoulder impairment 
(with or without hip involvement), which nicely fits the 
observed predominant prevalence of upper limb involve-
ment in this subgroup.
Midfoot arthritis (tarsitis) is a severe involvement of the 
feet in young people with SpA, especially in the Mexican 
population.27–29 Our results confirm these findings: the 
highest prevalence of tarsitis was reported in Latin Amer-
ican patients as well as in patients with Juv- SpA.
Enthesitis was very prevalent, almost in half. This symptom 
was more frequent in Latin American patients and less 
in European and North American patients. Interestingly, 
enthesitis, a phenomenon historically most associated with 
axSpA, was lowest in this category and far higher in patients 
with a diagnosis of PsA. Of note, the percentage of patients 
with enthesitis that was confirmed by imaging was rather 
low in all population groups. This highlights that imaging 
is rarely used to confirm enthesitis, and suggests that pain 
reported at different locations is often conveniently reported 
as enthesitis, but may rather be a symptom of widespread 
pain in the context of general sensitisation (secondary 
fibromyalgia). Interestingly in this regard, the highest mean 
number of different locations of all episodes of enthesitis was 
observed among patients with PsA, which was also the group 
with the highest prevalence of fibromyalgia according to the 
FiRST questionnaire. It has been proposed that a subgroup 
of patients with PsA with ‘more enthesitis than synovitis’ 
exists. Indeed, the classification criteria for psoriatic arthritis 
(CASPAR) recognise ‘enthesitis’ as a typical clinical feature 
of this disease by including it as one of the three entry mani-
festations.3 30 Due to the overlap between entheseal sites and 
the classic fibromyalgia tender points, these patients can 
easily be mixed up with fibromyalgia.
Finally, dactylitis (overall 15%) occurred most frequently 
in patients with PsA and confirms the view of dactylitis as 
a hallmark clinical feature of PsA.31 Classically, dactylitis 
involves feet more frequently than hands but our findings 
suggest that this may depend on the subtype of SpA: more 
than half of patients with ReA and IBD- SpA with dactylitis 
had dactylitis only of fingers, whereas more than half of 
patients with Juv- SpA had dactylitis only of the toes.
As expected, csDMARDs and glucocorticoids (either oral or 
by local injection) were frequently used among patients with 
peripheral joint disease. These findings are not surprising 
because, in accordance with the current ASAS- EULAR recom-
mendations, glucocorticoid injections and sulfasalazine may 
be considered in case of peripheral arthritis.32 The results for 
the treatment used for enthesitis partially reflect the current 
recommendations for associated- PsA enthesitis manage-
ment,33 whereby NSAIDs represent the first- line agents. If, 
indeed, much of the enthesitis reported by patients with PsA 
(and other SpA) reflects widespread pain rather than inflam-
mation at the insertion of the tendon, this recommendation 
may lead to overtreatment. Similarly, 34% of patients with 
enthesitis reported the use of csDMARDs ever, while EULAR 
and GRAPPA recommendations propose bDMARDs rather 
than csDMARDs for ‘active enthesitis’.33 34 Remarkably, clini-
cians were more concerned about glucocorticoid injections 
(only 8%), likely explained by the fear for tendon- rupture in 
weight- bearing entheseal sites.33
This study has weaknesses and strengths. One limita-
tion is the cross- sectional design of the study, which 
does not allow to evaluate cause- effect relationships. 
The second limitation is the difficulty of precisely eval-
uating peripheral manifestations that occurred before 
the actual study visit. This may lead to overcall or under- 
reporting and could not be adjusted for (recall bias). 
Another limitation, briefly discussed above, is that the 
proportion of patients with axSpA was larger than that 
of the other groups, which could have an impact on the 
overall prevalence of peripheral symptoms in this study. 
However, this high number of patients with axSpA led us 
to answer a question which is not really possible to answer 
based on the available literature,19 giving a reliable prev-
alence of peripheral musculoskeletal manifestations in 
these patients and confirming the necessity of treatment 
studies focused on these features. The most important 
strength of this PerSpA study is the worldwide coverage 
and the large number of participating centres which give 
the possibility to compare the different regions of the 
world. Moreover, this study included patients who clas-
sically belong to different domains allowing to conduct 
direct comparisons between entities.
In summary, we have presented here the worldwide clin-
ical picture of peripheral musculoskeletal manifestations 
in patients with a diagnosis belonging to the entire SpA 
spectrum. This study suggests that all different peripheral 
features can be found in all subtypes of SpA (including PsA), 
and that differences are quantitative rather than qualitative. 
It also suggests that peripheral and axial manifestations often 
coincide. Together, these observations reconfirm the overlap 
between entities in spite of different clinical diagnoses. Our 
results also confirm the high variability of peripheral muscu-
loskeletal manifestations in patients with SpA worldwide. 
This first description of the PerSpA cohort will serve as the 
basis for further ancillary analyses aiming at evaluating the 
inter- relationship of clinical manifestations and other SpA 
features, as well as the validity of existing outcome measures.
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